Albumin and Creatinine Tests Market Report 2026

The albumin and creatinine tests market size has grown exponentially in recent years. It will grow from $3.6 billion in 2025 to $4.4 billion in 2026 at a compound annual growth rate (CAGR) of 22.2%. The growth in the historic period can be attributed to limited availability of point-of-care testing devices, reliance on manual urine dipstick tests, increasing prevalence of kidney-related disorders, growing hospital and diagnostic laboratory infrastructure, rising awareness of kidney disease screening.

The albumin and creatinine tests market size is expected to see exponential growth in the next few years. It will grow to $9.65 billion in 2030 at a compound annual growth rate (CAGR) of 21.7%. The growth in the forecast period can be attributed to technological advancements in urine analyzers and cartridges, expansion of automated laboratory solutions, increasing adoption of glycated albumin testing, growing investment in diagnostic reagent innovation, integration of data analytics for early kidney disease detection. Major trends in the forecast period include increasing adoption of point-of-care albumin and creatinine tests, rising demand for automated urine analyzers, expansion of microalbumin test kits in early kidney disease detection, growing use of colorimetric and immunoassay reagents, enhanced accuracy through standardized calibration and control solutions.

The increasing incidence of chronic kidney diseases is expected to drive the growth of the albumin and creatinine tests market in the coming years. Chronic kidney disease (CKD) is characterized by the gradual loss of kidney function over time, in which the kidneys are unable to filter waste and excess fluids from the blood effectively, leading to toxin buildup and potential complications in multiple bodily systems. The rising occurrence of chronic kidney diseases is driven by an increase in risk factors such as diabetes, hypertension, and obesity. Albumin and creatinine tests aid in diagnosing and monitoring chronic kidney diseases by measuring protein levels, such as albumin, in the urine and assessing kidney function through creatinine levels, enabling early detection and management of kidney damage. For instance, in June 2023, Kidney Research UK, a UK-based nonprofit organization, reported that approximately 7.2 million people in the UK, representing over 10% of the population, are living with chronic kidney disease, including 3.25 million in advanced stages and 3.9 million in early stages. By 2033, the number of affected individuals is projected to rise to 7.61 million. Therefore, the rising incidence of chronic kidney disease is fueling growth in the albumin and creatinine tests market.

Major companies operating in the albumin and creatinine tests market are focusing on developing advanced digital diagnostic solutions, such as smartphone-enabled uACR testing, to improve early detection of chronic kidney disease and expand access to at-home testing. Smartphone-enabled uACR testing uses mobile phone cameras, AI-driven analysis, and test strips to measure the urine albumin-to-creatinine ratio, providing rapid and reliable results without the need for in-clinic visits. For instance, in November 2024, Healthy.io, an Israel-based digital diagnostics company, presented new clinical study results at ASN Kidney Week 2024, demonstrating that its smartphone-enabled Minuteful Kidney test delivers accuracy comparable to laboratory analyzers for measuring uACR. The study indicated that the AI-powered test reliably detects elevated albumin levels and supports early CKD detection, helping reduce barriers to testing and enabling proactive kidney health management.

In February 2024, Everly Health, a U.S.-based digital health and remote diagnostics company, partnered with the National Kidney Foundation (NKF) to expand access to at-home urine albumin-to-creatinine ratio (uACR) testing for early detection of chronic kidney disease. Through this partnership, Everly Health aims to enhance its kidney health screening offerings by integrating uACR and estimated glomerular filtration rate (eGFR) measures into its diagnostic solutions for health plans and employers, while the NKF supports education, awareness, and outreach initiatives to improve early detection among underserved populations. The National Kidney Foundation is a U.S.-based nonprofit organization focused on kidney health and disease prevention.

Major companies operating in the albumin and creatinine tests market are Siemens Healthineers Company, Roche Diagnostics GmbH, Thermo Fisher Scientific Inc., Abbott Laboratories, FUJIFILM Corporation, Laboratory Corporation of America Holdings, Sysmex Corporation, Ortho Clinical Diagnostics Inc., Randox Laboratories Ltd., Nova Biomedical Corporation, Eagle Biosciences Inc., Sekisui Diagnostics LLC, BTNX Inc., RayBiotech Life Inc., ARKRAY Inc., PromoCell GmbH, Arbor Assays Inc., Teco Diagnostics Inc., J. Mitra & Co. Pvt. Ltd., Anamol Laboratories Pvt. Ltd.

North America was the largest region in the albumin and creatinine tests market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the albumin and creatinine tests market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the albumin and creatinine tests market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the albumin and creatinine tests market by increasing costs for imported analyzers, test kits, and reagents, particularly affecting automated urine analyzers and microalbumin test kits. Regions like north america, europe, and asia-pacific experience higher procurement costs, leading to slower adoption in hospitals and diagnostic labs. However, tariffs have encouraged local manufacturing, development of domestic reagent solutions, and innovation in point-of-care testing devices, creating new opportunities for regional suppliers.

The albumin and creatinine tests market research report is one of a series of new reports that provides albumin and creatinine tests market statistics, including albumin and creatinine tests industry global market size, regional shares, competitors with a albumin and creatinine tests market share, detailed albumin and creatinine tests market segments, market trends and opportunities, and any further data you may need to thrive in the albumin and creatinine tests industry. This albumin and creatinine tests market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Albumin and creatinine tests are diagnostic assessments that combine these two measurements to provide a more accurate evaluation of kidney health by comparing the concentrations of albumin and creatinine in urine samples. This ratio helps adjust albumin levels relative to creatinine, which can vary due to factors such as hydration status.

The primary products used in albumin and creatinine tests include dipsticks and kits, analyzers, cartridges, reagents, and others. Dipsticks and kits are essential tools for evaluating kidney function, particularly for detecting albuminuria, a key indicator of chronic kidney disease. The different test types include blood and urine creatinine, urine albumin, and glycated albumin, and they are used by end users such as hospitals and clinics, diagnostic laboratories, research laboratories and institutes, and others.

The albumin and creatinine tests market consists of revenues earned by entities by providing services such as diagnostic testing services, home testing kits, automated test solutions, and data analysis and reporting. The market value includes the value of related goods sold by the service provider or included within the service offering. The albumin and creatinine tests market also includes sales of reagents and consumables, testing instruments, home test kits, and software solutions. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.